20/20 Biolabs, Inc. entered into a 120-day standstill agreement with Streeterville Capital, LLC on July 16, 2026, preventing Streeterville from converting series E convertible preferred stock into common stock unless the stock price is at least 10% above the Nasdaq Minimum Price. Additionally, the company received a Nasdaq delisting notice on July 17, 2026, due to following the $1.00 closing bid price requirement for 30 consecutive business days. The company has until January 13, 2027, to regain compliance. 20/20 Biolabs, Inc. is a biotechnology company that provides laboratory testing services.